Dasatinib-Induced Colitis with Rectal Sparing in a Patient with Chronic Myeloid Leukemia (Chronic Phase) on Dasatinib as an Upfront Therapy: Case Report

Dasatinib is a BCR-ABL tyrosine kinase inhibitor which was approved in 2006 for the treatment of adults diagnosed with Philadelphia chromosome-positive (Ph+) chronic myeloid leukemia (CML) in chronic phase (CP) and accelerated (myeloid or lymphoid blast) phase and CML with resistance or intolerance...

Descripción completa

Detalles Bibliográficos
Autores principales: Maat, Zakaria, Mushtaq, Kamran, Yassin, Mohamed A.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: S. Karger AG 2021
Materias:
Case Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8613618/
https://www.ncbi.nlm.nih.gov/pubmed/34899234
http://dx.doi.org/10.1159/000516794
_version_ 1784603674892304384
author Maat, Zakaria
Mushtaq, Kamran
Yassin, Mohamed A.
author_facet Maat, Zakaria
Mushtaq, Kamran
Yassin, Mohamed A.
author_sort Maat, Zakaria
collection PubMed
description Dasatinib is a BCR-ABL tyrosine kinase inhibitor which was approved in 2006 for the treatment of adults diagnosed with Philadelphia chromosome-positive (Ph+) chronic myeloid leukemia (CML) in chronic phase (CP) and accelerated (myeloid or lymphoid blast) phase and CML with resistance or intolerance to prior therapy including imatinib and in adults with Ph+ acute lymphoblastic leukemia. Common adverse reactions (>15%) in patients diagnosed with CP-CML include myelosuppression, fluid retention, and diarrhea. We report a 34-year-old Filipino female patient who received dasatinib as upfront therapy for the treatment of CP-CML who experienced chronic diarrhea for 2 months, which progressed to colitis.
format Online
Article
Text
id pubmed-8613618
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher S. Karger AG
record_format MEDLINE/PubMed
spelling pubmed-86136182021-12-09 Dasatinib-Induced Colitis with Rectal Sparing in a Patient with Chronic Myeloid Leukemia (Chronic Phase) on Dasatinib as an Upfront Therapy: Case Report Maat, Zakaria Mushtaq, Kamran Yassin, Mohamed A. Case Rep Oncol Case Report Dasatinib is a BCR-ABL tyrosine kinase inhibitor which was approved in 2006 for the treatment of adults diagnosed with Philadelphia chromosome-positive (Ph+) chronic myeloid leukemia (CML) in chronic phase (CP) and accelerated (myeloid or lymphoid blast) phase and CML with resistance or intolerance to prior therapy including imatinib and in adults with Ph+ acute lymphoblastic leukemia. Common adverse reactions (>15%) in patients diagnosed with CP-CML include myelosuppression, fluid retention, and diarrhea. We report a 34-year-old Filipino female patient who received dasatinib as upfront therapy for the treatment of CP-CML who experienced chronic diarrhea for 2 months, which progressed to colitis. S. Karger AG 2021-10-18 /pmc/articles/PMC8613618/ /pubmed/34899234 http://dx.doi.org/10.1159/000516794 Text en Copyright © 2021 by S. Karger AG, Basel https://creativecommons.org/licenses/by-nc/4.0/This article is licensed under the Creative Commons Attribution-NonCommercial-4.0 International License (CC BY-NC) (http://www.karger.com/Services/OpenAccessLicense). Usage and distribution for commercial purposes requires written permission.
spellingShingle Case Report
Maat, Zakaria
Mushtaq, Kamran
Yassin, Mohamed A.
Dasatinib-Induced Colitis with Rectal Sparing in a Patient with Chronic Myeloid Leukemia (Chronic Phase) on Dasatinib as an Upfront Therapy: Case Report
title Dasatinib-Induced Colitis with Rectal Sparing in a Patient with Chronic Myeloid Leukemia (Chronic Phase) on Dasatinib as an Upfront Therapy: Case Report
title_full Dasatinib-Induced Colitis with Rectal Sparing in a Patient with Chronic Myeloid Leukemia (Chronic Phase) on Dasatinib as an Upfront Therapy: Case Report
title_fullStr Dasatinib-Induced Colitis with Rectal Sparing in a Patient with Chronic Myeloid Leukemia (Chronic Phase) on Dasatinib as an Upfront Therapy: Case Report
title_full_unstemmed Dasatinib-Induced Colitis with Rectal Sparing in a Patient with Chronic Myeloid Leukemia (Chronic Phase) on Dasatinib as an Upfront Therapy: Case Report
title_short Dasatinib-Induced Colitis with Rectal Sparing in a Patient with Chronic Myeloid Leukemia (Chronic Phase) on Dasatinib as an Upfront Therapy: Case Report
title_sort dasatinib-induced colitis with rectal sparing in a patient with chronic myeloid leukemia (chronic phase) on dasatinib as an upfront therapy: case report
topic Case Report
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8613618/
https://www.ncbi.nlm.nih.gov/pubmed/34899234
http://dx.doi.org/10.1159/000516794
work_keys_str_mv AT maatzakaria dasatinibinducedcolitiswithrectalsparinginapatientwithchronicmyeloidleukemiachronicphaseondasatinibasanupfronttherapycasereport
AT mushtaqkamran dasatinibinducedcolitiswithrectalsparinginapatientwithchronicmyeloidleukemiachronicphaseondasatinibasanupfronttherapycasereport
AT yassinmohameda dasatinibinducedcolitiswithrectalsparinginapatientwithchronicmyeloidleukemiachronicphaseondasatinibasanupfronttherapycasereport

Ejemplares similares